Abstract
Motor neuron diseases such as amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA) are neurodegenerative diseases, which cause progressive paralysis and premature death in affected adults and children. The treatment rational for these diseases is to halt or delay the degeneration of motor neurons but to date there are no effective drugs. This may however change with recent advances in gene therapy using lentiviral vectors. These vectors can transfer genes to motor neurons with high efficiency and give long term expression. One of these vector systems, based on the equine infectious anaemia virus (EIAV), can insert genes into the cells of the central nervous system after remote delivery including delivery into the muscle by exploiting retrograde transport pathways. This opens up the exciting possibity of rescuing the denervation of key muscle groups in patients by simple injections of these neurotropic lentiviral vectors into the muscle. This review will describe the general features of lentiviral vectors derived from the EIAV. It will then describe some key examples of gene transfer and genetic correction in animal models of motor neuron disease. The prospects for the clinical evaluation of lentiviral vectors for the treatment of human motor neuron disease will be outlined.
Keywords: eiav, motor neuron, motor neuron diseases, als, sma, ientiviral, gene therapy
Current Gene Therapy
Title: Non-Primate EIAV-Based Lentiviral Vectors as Gene Delivery System for Motor Neuron Diseases
Volume: 4 Issue: 3
Author(s): M. Azzouz and N. Mazarakis
Affiliation:
Keywords: eiav, motor neuron, motor neuron diseases, als, sma, ientiviral, gene therapy
Abstract: Motor neuron diseases such as amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA) are neurodegenerative diseases, which cause progressive paralysis and premature death in affected adults and children. The treatment rational for these diseases is to halt or delay the degeneration of motor neurons but to date there are no effective drugs. This may however change with recent advances in gene therapy using lentiviral vectors. These vectors can transfer genes to motor neurons with high efficiency and give long term expression. One of these vector systems, based on the equine infectious anaemia virus (EIAV), can insert genes into the cells of the central nervous system after remote delivery including delivery into the muscle by exploiting retrograde transport pathways. This opens up the exciting possibity of rescuing the denervation of key muscle groups in patients by simple injections of these neurotropic lentiviral vectors into the muscle. This review will describe the general features of lentiviral vectors derived from the EIAV. It will then describe some key examples of gene transfer and genetic correction in animal models of motor neuron disease. The prospects for the clinical evaluation of lentiviral vectors for the treatment of human motor neuron disease will be outlined.
Export Options
About this article
Cite this article as:
Azzouz M. and Mazarakis N., Non-Primate EIAV-Based Lentiviral Vectors as Gene Delivery System for Motor Neuron Diseases, Current Gene Therapy 2004; 4 (3) . https://dx.doi.org/10.2174/1566523043346291
DOI https://dx.doi.org/10.2174/1566523043346291 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Stem Cells: In Sickness and in Health
Current Stem Cell Research & Therapy Therapeutic Potential of Metabotropic Glutamate Receptor Modulators
Current Neuropharmacology Editorial [Hot Topic: Animal Models for Neurodegenerative Diseases Associated to Accumulation of Misfolded Protein Aggregates (Executive Guest Editor: Claudio Soto)]
Current Pharmaceutical Design Protein Kinase C Isozymes: Memory Therapeutic Potential
Current Drug Targets - CNS & Neurological Disorders Functional Interactions of Tau and their Relevance for Alzheimers Disease
Current Alzheimer Research Neurotrophin Receptor Signaling as a Therapeutic Target for Huntington's Disease
CNS & Neurological Disorders - Drug Targets Targeting Hsp90 in Non-Cancerous Maladies
Current Topics in Medicinal Chemistry Childhood Maltreatment and Stress-Related Psychopathology: The Epigenetic Memory Hypothesis
Current Pharmaceutical Design The NMDA Receptor/Ion Channel Complex: A Drug Target for Modulating Synaptic Plasticity and Excitotoxicity
Current Pharmaceutical Design Alzheimer’s Disease and Environmental Exposure to Lead: The Epidemiologic Evidence and Potential Role of Epigenetics
Current Alzheimer Research PERK-opathies: An Endoplasmic Reticulum Stress Mechanism Underlying Neurodegeneration
Current Alzheimer Research Current Progresses of Novel Natural Products and Their Derivatives/ Analogs as Anti-Alzheimer Candidates: an Update
Mini-Reviews in Medicinal Chemistry Multi-Target Directed Compounds with Antioxidant and/or Anti- Inflammatory Properties as Potent Agents for Alzheimer’s Disease
Medicinal Chemistry Rheumatoid Arthritis: Genetic Variants as Biomarkers of Cardiovascular Disease
Current Pharmaceutical Design Neuroprotection: The Emerging Concept of Restorative Neural Stem Cell Biology for the Treatment of Neurodegenerative Diseases
Current Neuropharmacology Trends and Applications of Brain Computer Interfaces
Current Signal Transduction Therapy The Panomics Approach in Neurodegenerative Disorders
Current Medicinal Chemistry Effect of Drugs in Cells and Tissues by NMR Spectroscopy
Current Topics in Medicinal Chemistry Intrathecal Administration of Melatonin Ameliorates the Neuroinflammation- Mediated Sensory and Motor Dysfunction in A Rat Model of Compression Spinal Cord Injury
Current Molecular Pharmacology Inhibition of Human Serine Racemase, an Emerging Target for Medicinal Chemistry
Current Drug Targets